KMT2A and leukemia: We next determined the in vivo anti-leukemia efficacy of ziftomenib and/or venetoclax or OTX015, at well-tolerated dose levels of these combinations, in NSG mice engrafted with PD AML cells harboring MLL1-r (MLL-AF9) and FLT3-TKD (sample #1).